Dymista approved in Europe

Dymista has received medical approval in Europe via the decentralized
registration procedure. Dymista is approved for the treatment of seasonal and
perennial allergic rhinitis. National registration processes, including
negotiations regarding pricing and reimbursement, will now follow in each
country prior to launch. Launches are anticipated in 2013 in several countries.

"Patients in Europe that suffer from allergic rhinitis will soon have access to
a better treatment option than the current standard therapy. The faster and more
complete effect offers significant benefit to the growing numbers of patients
suffering from this difficult and inhibiting disease", said Anders Lönner, CEO
of Meda AB.

About Dymista

Dymista is a novel nasal formulation of azelastine and fluticasone. The efficacy
and safety of Dymista has been documented in several studies with more than
4,000 patients, including a long-term safety study with more than 600 patients.
Dymista has consistently showed faster and more complete symptom relief than
standard treatment. Dymista has been available in the US since September 2012.
For further inquiries, please contact:

Anders Larnholt, Vice      ph: +46 709-458 878
President Corporate
Development & IR
Paula Treutiger, Investor  ph: +46 733-666 599
Relations                  paula.treutiger@meda.se

MEDA AB (publ) is a leading international specialty pharma company. Meda’s
products are sold in 120 countries worldwide and the company is represented by
its own organizations in 50 countries. The Meda share is listed under
Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more,
visit www.meda.se.

Forward-looking statements
This press release is not an offer to sell or a solicitation to buy shares in
Meda. This press release also contains certain forward-looking statements with
respect to certain future events and Meda’s potential financial performance.
These forward-looking statements can be identified by the fact that they do not
relate only to historical or current facts, and may sometimes include words such
as “may”, “will”, “seek”, “anticipate”, “expect”, “estimate”, “intend”, “plan”,
“forecast”, “believe” or other words of similar meaning. These forward looking
statements reflect the current expectations on future events of the management
at the time such statements are made, but are made subject to a number of risks
and uncertainties. In the event such risks or uncertainties materialize, Meda’s
results could be materially affected. The risks and uncertainties include, but
are not limited to, risks associated with the inherent uncertainty of
pharmaceutical research and product development, manufacturing and
commercialization, the impact of competitive products, patents, legal
challenges, government regulation and approval, Meda’s ability to secure new
products for commercialization and/or development and other risks and
uncertainties detailed from time to time in Meda AB’s interim or annual reports,
prospectuses or press releases. Listeners and readers are cautioned that no
forward-looking statement is a guarantee of future performance and that actual
result could differ materially from those contained in the forward-looking
statements. Meda does not intend, nor undertakes, to update any such forward
looking statements.